Pacific Biosciences of California, Inc. PACB
Set alert
At close · Oct 30
After hours · Oct 30, 7:34 PM ET
- YTD
- +39.30%
- 1 year
- +34.28%
- Open
- 2.75
- Prev close
- 2.90
- Mkt cap
- 809.71M
- Vol
- 13.74M
- Avg vol
- 11.85M
- EPS
- -0.43
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.41
- High
- 2.82
- Forward P/E
- -2.84
- Beta
- 2.01
- Short ratio
- 4.46
- Inst. own
- 84.53%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.01
- 200-d avg
- 2.02
- 1y target
- 3.02
5D chart
Signals (78)
| Name | Time | Ago |
|---|---|---|
| RSI: Overbought | Oct 30, 3:35 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:00 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 2:35 PM | 2 days ago |
| RSI: Oversold | Oct 30, 2:10 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 2:05 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:25 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:15 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:00 PM | 2 days ago |
| SMA: Bullish | Oct 30, 11:55 AM | 2 days ago |
| RSI: Oversold | Oct 30, 11:25 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 11:10 AM | 2 days ago |
| RSI: Oversold | Oct 30, 10:05 AM | 2 days ago |
| RSI: Oversold | Oct 30, 9:50 AM | 2 days ago |
| RSI: Oversold | Oct 30, 9:40 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 9:30 AM | 2 days ago |
| RSI: Oversold | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bullish | Oct 29, 3:50 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:50 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:30 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 2:30 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:50 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 12:50 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:40 PM | 3 days ago |
| SMA: Bullish | Oct 29, 11:55 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 11:05 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:45 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:25 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:25 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:10 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:10 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:50 AM | 3 days ago |
| SMA: Bearish | Oct 29, 9:35 AM | 3 days ago |
| SMA: Bearish | Oct 29, 9:35 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 28, 3:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:30 PM | 4 days ago |
| RSI: Oversold | Oct 28, 3:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:25 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:05 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:20 AM | 4 days ago |
| RSI: Overbought | Oct 28, 9:40 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 9:35 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 27, 3:50 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:40 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:30 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:35 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:30 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:20 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 2:20 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:30 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:30 PM | 5 days ago |
| RSI: Overbought | Oct 27, 10:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:35 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:30 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:10 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:00 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:30 PM | 6 days ago |
| RSI: Overbought | Oct 26, 11:35 AM | 6 days ago |
| RSI: Overbought | Oct 26, 10:45 AM | 6 days ago |
News
2 days ago zacks.com
Pacific Biosciences of California (PACB) Rises As Market Takes a Dip: Key Facts
In the latest trading session, Pacific Biosciences of California (PACB) closed at $2.9, marking a +2.47% move from the previous day.
4 days ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
4 days ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Pulmonx (NASDAQ:LUNG) stock increased by 33.1% to $2.63 during Wednesday's regular session. The company's market cap stands at $85.0 million. As per the press release, Q3 earnings came out…
4 days ago benzinga.com
Vertiv, Evercore, Brinker, GE HealthCare And Other Big Stocks Moving Higher On Wednesday
U.S. stocks mixed; Dow gained ~100 points. Vertiv jumped 13.3% on strong results and raised guidance; Ultralife soared 145.8% on buyout news.
5 days ago globenewswire.com
PacBio to Participate in Upcoming Investor Conferences
MENLO PARK, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be…
5 days ago zacks.com
Here's Why You Should Hold PacBio Stock in Your Portfolio for Now
PACB's growing clinical adoption, advanced sequencing technologies and rising consumables sales support growth, but funding headwinds and margin pressures persist.
1 week ago zacks.com
Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors
The latest trading day saw Pacific Biosciences of California (PACB) settling at $2.06, representing a -3.74% change from its previous close.
-
1 week ago benzinga.com
PacBio And Verily Health Announce Multi-Year Strategic Collaboration To Integrate PacBio HiFi Sequencing With Verily Health’s Governed Data And AI Platform
PacBio (NASDAQ:PACB), developer of the world’s most advanced sequencing technologies, and Verily Health Inc., a healthcare data intelligence company, announced today a multi-year strategic…
1 week ago globenewswire.com
PacBio and Verily Health Announce Multi-Year Strategic Collaboration to Scale Long-Read Genomics for Biomedical AI
Verily Pre will connect PacBio HiFi Sequencing with governed cloud analysis, multimodal health data and AI-ready research workflows Verily Pre will connect PacBio HiFi Sequencing with governed cloud…
2 weeks ago zacks.com
Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors
In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.99, indicating a -2.93% shift from the previous trading day.
2 weeks ago globenewswire.com
PacBio to Report Third Quarter 2026 Financial Results on November 4, 2026
MENLO PARK, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2026 financial results on…
2 weeks ago zacks.com
PacBio Teams With TychoBio to Advance AI-Driven RNA Therapeutics
PACB partners with TychoBio to harness AI and long-read RNA sequencing for rare disease therapies, aiming to improve drug efficacy and safety through advanced data models.
2 weeks ago defenseworld.net
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap Down – Here’s Why
Pacific Biosciences of California, Inc. (NASDAQ: PACB - Get Free Report) shares gapped down before the market opened on Monday. The stock had previously closed at $2.33, but opened at $2.24. Pacific…
3 weeks ago defenseworld.net
Insider Selling: Pacific Biosciences of California (NASDAQ:PACB) Insider Sells $2,058,244.65 in Stock
Pacific Biosciences of California, Inc. (NASDAQ: PACB - Get Free Report) insider James Gibson II sold 661,815 shares of Pacific Biosciences of California stock in a transaction that occurred on…
3 weeks ago zacks.com
Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market Today
The latest trading day saw Pacific Biosciences of California (PACB) settling at $2.3, representing a -15.44% change from its previous close.
3 weeks ago benzinga.com
Apogee Enterprises Posts Upbeat Q2 Earnings, Joins Constellation Energy, Freshworks And Other Big Stocks Moving Higher On Tuesday
U.S. stocks rose; Apogee surged 10% on strong results and raised guidance, while Option Care, Ginkgo, PacBio and others posted double-digit gains.
-
3 weeks ago benzinga.com
PacBio, TychoBio Collaborate Over Generation Of RNA Data To Train Models For RNA Therapy Design
PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, and TychoBio, an AI drug discovery company, today announced a collaboration to generate full-length RNA data…
3 weeks ago globenewswire.com
PacBio and TychoBio Collaborate to Train AI Models for Rare Disease RNA Therapeutics
PacBio Kinnex sequencing will generate full-length transcript data to help advance TychoBio's drug discovery models PacBio Kinnex sequencing will generate full-length transcript data to help advance…
4 weeks ago zacks.com
Pacific Biosciences of California (PACB) Rises Higher Than Market: Key Facts
Pacific Biosciences of California (PACB) concluded the recent trading session at $2.54, signifying a +1.2% move from its prior day's close.
1 month ago schaeffersresearch.com
3 Biotech Stocks Put Traders Are Targeting Today
Nektar Therapeutics (NASDAQ:NKTR), Quantum-Si Inc (NASDAQ:QSI), and Pacific Biosciences of California Inc (NASDAQ:PACB) are all attracting elevated options activity today, as biotech stocks make…
1 month ago benzinga.com
Progress Software, Nft And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
U.S. stock futures were mixed as Progress Software fell after results; Corteva, NFT, Vivakor and other stocks also dropped in premarket trading.
1 month ago defenseworld.net
Pacific Biosciences of California (NASDAQ:PACB) Stock Sees Heavy Call Option Buying
Pacific Biosciences of California, Inc. (NASDAQ: PACB - Get Free Report) was the recipient of unusually large options trading on Wednesday. Stock investors acquired 13,687 call options on the stock.…
1 month ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers NewGenIvf Group (NASDAQ:NIVF) shares moved upwards by 147.1% to $0.18 during Wednesday's regular session. Tenon Medical (NASDAQ:TNON) stock increased by 47.25% to $4.02. The market value of…
1 month ago defenseworld.net
Pacific Biosciences of California (NASDAQ:PACB) Shares Climb 6.1% – Still a Buy?
Shares of Pacific Biosciences of California, Inc. (NASDAQ: PACB - Get Free Report) rose 6.1% on Monday. The company traded as high as $1.68 and last traded at $1.7190. 2,798,059 shares traded hands…
1 month ago benzinga.com
Kodiak Sciences, AMC Entertainment, Agenus And Other Big Stocks Moving Higher On Monday
U.S. stocks fell Monday, while Kodiak Sciences surged 174% after positive Phase 3 eye disease trial results; several small caps also rallied.
1 month ago zacks.com
Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know
In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.62, marking a +2.53% move from the previous day.
1 month ago marketbeat.com
Pacific Biosciences Targets Clinical Growth, $40M Savings With HiFi Sequencing Push
Pacific Biosciences of California NASDAQ: PACB is maintaining its existing strategy while sharpening execution around clinical genomics, cost controls and the rollout of products designed to improve…
1 month ago zacks.com
Why Pacific Biosciences of California (PACB) Outpaced the Stock Market Today
In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.38, indicating a +2.99% shift from the previous trading day.
1 month ago seekingalpha.com
Pacific Biosciences of California, Inc. (PACB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Pacific Biosciences of California, Inc. (PACB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
-
1 month ago benzinga.com
UBS Assumes Pacific Biosciences at Neutral, Lowers Price Target of $1.35
UBS analyst Doug Schenkel assumes Pacific Biosciences (NASDAQ:PACB) with a Neutral rating and lowers Price Target of $1.35.
2 months ago benzinga.com
Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday
Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million. Other big gainers include CAPR, RZLV, CRML, and MAIR.
-
2 months ago benzinga.com
Pacific Biosciences Of California Approves Restructuring Plan To Align With Strategic Initiatives; Restructuring To Reduce Workforce By About 8%; Expects $30M-$40M Annualized Operating Expense Reduction By End Of 2027; Estimates $2M Pre-Tax Charges For Reduction In Force
On July 30, 2026, the Board of Directors (the "Board") of the Company approved a restructuring plan to continue to better align the Company’s organizational structure and resources with its strategic
-
2 months ago benzinga.com
Pacific Biosciences Lowers FY2026 Sales Guidance from $165.000M-$175.000M to $155.000M-$165.000M vs $166.790M Est
Pacific Biosciences (NASDAQ:PACB) lowers FY2026 sales outlook from $165.000 million-$175.000 million to $155.000 million-$165.000 million vs $166.790 million estimate.
-
2 months ago benzinga.com
Pacific Biosciences of California Appoints Mark Van Oene As President, CEO, Effective Immediately, Succeeding Christian Henry
Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly accurate sequencing solutions, today announced that its Board of Directors has appointed…
-
2 months ago benzinga.com
Pacific Biosciences Q2 Adj. EPS $(0.14) Misses $(0.13) Estimate, Sales $39.007M Miss $40.067M Estimate
Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.13) by 7.69 percent. This is a 7.69 percent decrease over losses of…
4 months ago benzinga.com
Cathie Wood Sells Robinhood Stock, Doubles Down On This George Soros-Backed AI Stock
On Wednesday, June 10, 2026, Ark Invest sold $7.8M in Robinhood shares Wednesday while adding 141,502 shares of Kodiak AI
-
5 months ago benzinga.com
Blank Bio Closes $7.2M Seed Financing And Strategic Collaboration With Pacific Biosciences
Collaboration with PacBio will generate long-read bulk RNA-seq data to advance patient-level prediction from tumor transcriptomesBlank Bio, an applied AI research lab training foundation models for…
-
5 months ago benzinga.com
Barclays Maintains Underweight on Pacific Biosciences, Raises Price Target to $1.5
Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Underweight and raises the price target from $1 to $1.5.
-
5 months ago benzinga.com
Pacific Biosciences Sees FY2026 Sales $165.000M-$175.000M vs $173.371M Est
Pacific Biosciences (NASDAQ:PACB) sees FY2026 sales of $165.000 million-$175.000 million vs $173.371 million analyst estimate.
-
5 months ago benzinga.com
Pacific Biosciences Q1 Adj. EPS $(0.12) Beats $(0.14) Estimate, Sales $37.178M Miss $39.986M Estimate
Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.14) by 7.69 percent. This is a 20 percent increase over losses of…
-
6 months ago benzinga.com
PacBio And PerkinElmer Subsidiary Covaris Announce That A Joint Workflow Has Been Developed For Robust HiFi Sequencing Of Formalin-Fixed, Paraffin-Embedded (FFPE) Tissue Samples
The protocol will be formally presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting. This solution integrates Covaris' truXTRA FFPE extraction technology with…
-
8 months ago benzinga.com
Barclays Downgrades Pacific Biosciences to Underweight, Lowers Price Target to $1.5
Barclays analyst Luke Sergott downgrades Pacific Biosciences (NASDAQ:PACB) from Equal-Weight to Underweight and lowers the price target from $2 to $1.5.
8 months ago benzinga.com
Insights into Pacific Biosciences Q4 Earnings
Insights into Pacific Biosciences Q4 Earnings
-
8 months ago benzinga.com
Pacific Biosciences Q4 Adj. EPS $(0.12) Beats $(0.15) Estimate, Sales $44.645M Beat $42.530M Estimate
Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 18.37 percent. This is a 40 percent increase over losses of…
8 months ago benzinga.com
Earnings Scheduled For February 12, 2026
Earnings Scheduled For February 12, 2026
8 months ago benzinga.com
Uncovering Potential: Pacific Biosciences's Earnings Preview
Uncovering Potential: Pacific Biosciences's Earnings Preview
-
9 months ago benzinga.com
PacBio Completes Sale Of Select IP And Other Assets To Illumina For $48.1M In Net Cash
PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the completion of the sale of select intellectual property and other assets related to…
-
9 months ago benzinga.com
PacBio Plans Strategic Collaboration With n-Lorem Foundation And EspeRare To Advance Long-Read Whole-Genome Sequencing For Individualized ASO Therapies In Ultra-Rare Genetic Diseases
PacBio (NASDAQ:PACB), developer of the world's most advanced sequencing technologies, today announced plans to pursue a strategic collaboration with the n-Lorem Foundation and EspeRare that we…
-
9 months ago benzinga.com
PacBio To Employ PacBio HiFi Whole-Genome Sequencing To Probe Sudden Unexplained Death In Childhood
PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced that a UW Medicine and Seattle Children's research effort led by Danny Miller, MD, PhD, and…
-
9 months ago benzinga.com
PacBio Reports Q4 2025 Revenue Of ~$44.6M; FY25 Revenue Of ~$160M
PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced preliminary unaudited revenue for the fourth quarter of 2025 and full year 2025 of $44.6…